



06727/012001 Attorney Docket No. SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED) Serial No. 10/624,380 **Applicant** Robert Mulroy et al. INFORMATION DISCLOSURE July 22, 2003 STATEMENT BY APPLICANT Filing Date (Use several sheets if necessary) Group 1632 (37 C.F.R. § 1.98(b)) **IDS Filed** March 28, 2005 **Customer Number** 21559

	-		U.S. PATENT	DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patent	ee or Applicant	Class	Subclass	Filing Date (If Appropriate)
RAW	4,692,332	09/08/87	John McMich	ael	424	88	01/18/85
	4,873,316	10/10/89	Harry Meade	et al.	800	7	06/23/87
	4,877,610	10/31/89	John McMich	ael	424	88	08/18/87
	4,966,753	10/30/90	John McMich	ael	424	88	06/16/89
	4,970,071	11/13/90	John McMich	ael	424	88	09/26/89
	5,130,415	07/14/92	Mario Tecce	et al.	530	324	07/24/89
	5,206,153	04/27/93	Taiki Tamaok	i et al.	435	69.7	03/16/92
	5,302,698	04/12/94	Tomonori Mo	rinaga et al.	530	350	04/27/90
	5,322,775	06/21/94	Anthony Clark	c et al.	435	69.1	11/22/91
	5,384,250	01/24/95	Robert A. Mu	rgita	435	69.6	10/08/93
	5,589,604	12/31/96	William Droha	an et al.	800	7	05/23/94
	5,633,076	05/27/97	Herman DeBo	per et al.	800	25	11/16/93
	5,639,940	06/17/97	lan Garner et	al	800	7	03/03/94
	5,648,243	07/15/87	David Hurwitz	et al.	435	69.6	09/21/94
	5,723,585	03/03/98	Joffre Baker	et al.	530	413	05/17/95
	5,766,884	06/16/98	Tim M. Towns	es et al.	800	5	06/06/95
	5,827,690	10/27/98	Harry Meade	et al.	800	7	12/20/93
	5,831,141	11/03/98	Henryk Lubor	n et al.	800	7	09/10/92
	5,843,705	12/01/98	Paul Ditullio e	et al.	800	7	02/21/95
RAW	5,843,776	12/01/98	Taiki Tamaok	i et al.	435	325	06/06/95
EXAMINER		•	-	DATE CONSIDERE	D		

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No. 06727/012001	06727/012001
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
STATEMENT	ON DISCLOSURE TBY APPLICANT	Filing Date	July 22, 2003
(Use several sheets if necessary)		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

	<u> </u>	 	U.S. PATENT	DOCUMENTS			
Examine Initia		Publication Date	Paten	tee or Applicant	Class	Subclass	Filing Date (If Appropriate)
RAI	5,965,528	10/12/99	Robert A. Mu	rgita	514	12	01/24/95
	6,013,857	01/11/00	Herman A. D	eboer et al.	800	15	06/05/95
	6,288,034	09/11/01	Robert A. Mu	rgita	514	12	11/05/98
RAW	6,331,611	12/18/01	Robert A. Mu	rgita	530	350	07/21/95
	FOI	REIGN PATENT	OR PUBLISHE	FOREIGN PATENT	APPLICATION)N	
Examine Initia		Publication Date		Country or atent Office	Class	Subclass	Translation (Yes/No)
RAV	FP 0 001 812	05/16/79	Europe				
RAW	FP 0 487 229	09/24/97	Europe				
RAW	JP 2005866	01/10/90	Japan (Abstra	act)			
RAV	WO 86/04241	07/31/86	PCT				
RAW	WO 93/05774	04/01/93	PCT				
RAW	WO 94/10199	05/11/94	PCT				
RA	W WO 95/00637	01/05/95	PCT	·			
RAV	WO 96/09377	03/28/96	PCT				
RAW	WO 96/22787	08/01/96	PCT				
RAW	WO 01/15709	03/08/01	PCT				
	OTHER DO	CUMENTS (INCL	UDING AUTHO	OR, TITLE, DATE, PL	ACE OF PUB	LICATION)	
RAW Abramsky et al., "A Role of Alpha-Fetoprotein in Autoimmune Diseases," Annals New York Academy of Sciences 417:108-116 (1983).							
RAW		, "Alpha-Fetoprol 1997 2:1-7 (1982).		Experimental Allergi	c Encephalon	nyelitis," <i>Jour</i>	mal of
EXAMIN	IER		•	DATE CONSIDER	ED		
	IER: Initial citation consi h the next communication		through citation	if not in conformanc	e and not con	isidered. Inc	lude copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No. 06727/012001	06727/012001
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
STATEMEN'	ON DISCLOSURE T BY APPLICANT	Filing Date	July 22, 2003
(Use several s	heets if necessary)	Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

XAMINER	DATE CONSIDERED				
RAW	Galarneau et al., "The Alpha ₁ -Fetoprotein Locus is Activated by a Nuclear Receptor of the <i>Drosophila</i> FTZ-F1 Family," <i>Molec. and Cell. Biol.</i> 16:3853-3865 (1996).				
	Dudich et al., "Growth-Regulative Activity of Human Alpha-Fetoprotein for Different Types of Tumor and Noma Cells," <i>Tumor Biology</i> 19:30-40 (1998).				
	Dattwyler et al., "Binding of Alpha-Foetoprotein to Murine T Cells," Nature 256:656-657 (1975).				
	Caturla et al., "The Thyroid Hormone Down-Regulates the Mouse Alpha-Foetoprotein Promoter," <i>Molec. and Cell. Endocrin.</i> 135:139-145 (1997). Cohen et al., "Suppression by Alpha-Fetoprotein of Murine Natural Killer Cell Activity Stimulated <i>in Vitro</i> and <i>in Vivo</i> by Interferon and Interleukin 2," <i>Scand. J. Immunol.</i> 23:211-223 (1986).				
	Buschman et al., "Experimental Myasthenia Gravis Induced in Mice by Passive Transfer of Human Myasthenic Immunoglobulin," <i>Journal of Neuroimmunology</i> 13:315-330 (1987).				
	Buamah et al., "Serum Alpha-Fetoprotein Heterogeneity as a Means of Differentiating Between Primary Hepatocellular Carcinoma and Hepatic Secondaries," Clinica. Chimica. Acta. 139:313-316 (1984).				
	Brenner et al., "Inhibitory Effect of Alpha-Fetoprotein on the Binding of Myasthenia Gravis Antibody to Acetylcholine Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 77:3635-3639 (1980).				
	Brenner et al., "Influence of Alpha-Fetoprotein on the in Vitro and in Vivo Immune Response to Acetylcholine Receptor," Annals New York Academy of Sciences 377:208-221 (1981).				
	Brenner et al., "Immunosuppression of Experimental Autoimmune Myasthenia Gravis by Alpha-Fetoprotein Rick Formation," <i>Immunology Letters</i> 3:163-167 (1981).				
	Boismenu et al., "Expression of Domains of Mouse Alpha-Fetoprotein in Escherichia Coli," Life Sciences 43:67: 681 (1988).				
	Birrer et al., "The Immunology of Alphafetoprotein," Journal of Tumor Marker Oncology 14:55-62 (1999).				
	Biddle et al., "Specific Cytoplasmic Alpha-Fetoprotein Binding Protein in MCF-7 Human Breast Cancer Cells an Primary Breast Cancer Tissue," Breast Cancer Research and Treatment 10:279-286 (1987).				
	Bennett et al., "Similarity Between Natural and Recombinant Human Alpha-Fetoprotein as Inhibitors of Estroger Dependent Breast Cancer Growth," Breast Cancer Research and Treatment 45:169-179 (1997).				
RAW	Aoyagi et al., "Differential Reactivity of Alpha-Fetoprotein with Lectins and Evaluation of its Usefulness in the Diagnosis of Hepatocellular Carcinoma," <i>Gann</i> 75:809-815 (1984).				

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No. 06727/012001	06727/012001
(MODIFIED)	PATENT AND TRADEMARK OFFICE Serial No.	Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
STATEMENT	N DISCLOSURE BY APPLICANT	Filing Date	July 22, 2003
(Use several sheets if necessary)		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

. . .

RAW	Gershwin et al., "The Influence of Alpha-Fetoprotein on Moloney Sarcoma Virus Oncogenesis: Evidence for Generation of Antigen Nonspecific Suppressor T Cells," <i>The Journal of Immunology</i> 121:2292-2297 (1978).				
-	Gibbs et al., "Structure, Polymorphism, and Novel Repeated DNA Elements Revealed by a Complete Sequence of the Human Alpha-Fetoprotein Gene," <i>Biochemistry</i> 26:1332-1343 (1987).				
	Giuliani et al., "Synthesis and Characterization of a Recombinant Fragment of Human Alpha-Fetoprotein with Antigenic Selectivity Versus Albumin," <i>Protein Engineering</i> 2:605-610 (1989).				
	Glazier et al., "Graft-Versus-Host Disease in Cyclosporin A-Treated Rats After Syngeneic and Autologous Bone Marrow Reconstitution," J. Exp. Med. 158:1-8 (1983).				
	Goidl et al., "Studies on the Mechanisms of Alpha-Fetoprotein Induction of Immune Suppressive Activity," from Developmental Immunobiology, Proceedings of the Fifth Irwin Strasburger Memorial Seminar on Immunology eds. Siskind et al., 35-55 (1979).				
	Hamel et al., "Phenotype and Function of Bone Marrow-Derived T- and Non-T-Cells Activated in Vitro by Alpha-Fetoprotein," Biological Activities of Alpha ₁ -Fetoprotein eds. Mizejewski et al. 1:167-177 (1987).				
	Heyward et al., "Early Detection of Primary Hepatocellular Carcinoma by Screening for Alpha-Fetoprotein in High-Risk Families," <i>The Lancet</i> 2:1161-1162 (1983).				
	Hooper et al., "Human AFP Inhibits Cell Proliferation and NK-Like Cytotoxic Activity Generated in Autologous, bu not in Allogeneic Mixed Lymphocyte Reactions," <i>Biological Activities of Alpha</i> ₁ -Fetoprotein eds. Mizejewski et al. 2:183-197 (1989).				
	Hooper et al., "Regulation of Murine T-Cell Responses to Autologous Antigens by Alpha-Fetoprotein," Cellular Immunology 63:417-425 (1981). Hooper et al., "Selective Inhibition of Murine T-Cell Proliferation and Lymphokine-Activated Natural Killer Cell Function by Alpha-Fetoprotein," Biological Activities of Alpha-Fetoprotein eds. Mizejewski et al. 1:153-165 (1987). Hooper et al., "Suppression of Primary and Secondary Autologous Mixed Lymphocyte Reactions by Murine Alphafetoprotein," Oncodevelopmental Biology and Medicine 3:151-160 (1982).				
	Hoskin et al., "Analysis of Pregnancy-Associated Immunoregulatory Pathways," Alpha-Fetoprotein and Congenital Disorders 59-78 (1985).				
	Hoskin et al., "In Vitro Activation of Bone Marrow-Derived T-and Non-T-Cell Subsets by Alpha-Fetoprotein," Cellular Immunology 96:163-174 (1985).				
RAW Hoskin et al., "Specific Maternal Anti-Fetal Lymphoproliferative Responses and Their Regulation by Immunosuppressive Factors," Clin. Exp. Immunol. 76:262-267 (1989).					
EXAMINER	DATE CONSIDERED				
	nitial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this next communication to applicant.				
	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				

SUBSTITUTE FORM PTO-1449	J.S. DEPARTMENT OF COMMERCE	Attorney Docket No. 06727/012001	06727/012001
(MODIFIED)	PATENT AND TRADEMARK OFFICE		10/624,380
		Applicant	Robert Mulroy et al.
STATEMENT 6	DISCLOSURE BY APPLICANT	Filing Date	July 22, 2003
(Use several sheets if necessary)		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

RAW	Innis et al., "Amplification of Alpha-Fetoprotein Complementary DNA by Insertion into a Bacterial Plasmid," Archives of Biochemistry and Biophysics 195:128-135 (1979).			
	Ishiguro et al., "Serum Alpha-Fetoprotein Subfractions in Patients with Primary Hepatoma or Hepatic Metastasis of Gastric Cancer," Cancer 55:156-159 (1985).			
	Jacobson et al., "Inhibition of Estrogen-Dependent Breast Cancer Growth by a Reaction Product of Alpha-Fetoprotein and Estradiol," Cancer Research 50:415-420 (1990).			
	Jiang et al., "Role of CD8+ T Cells in Murine Experimental Allergic Encephalomyelitis," Science 256:1213-1215 (1992).			
	Keller et al., "Immunosuppressive Properties of AFP: Role of Estrogens," from Onco-Developmental Gene Expression eds. Fishman et al. 287-295 (1976).			
	Kerr et al., "The Bladder as a Bioreactor: Urothelium Production and Secretion of Growth Hormone into Urine," Nat. Biotechnol. 16:75-79 (1998).			
	Kikutani et al., "The Murine Autoimmune Diabetes Model: NOD and Related Strains," Advances in Immunology 51:285-322 (1992).			
	Koyama et al., "Lectin Affinity Electrophoretic Demonstration of Tissue Specificity and Malignant Alteration of Human α-Fetoprotein Isoforms Produced in Transgenic Mice." Biochemical and Biophysical Research Communications 223:757-761 (1996).			
	Line et al., "Medical Potential of AFP as a Tumor Imaging Agent," Biological Activities of Alpha-Fetoprotein eds Mizejewski et al. 2:139-148 (1989).			
	Lu et al., "Alpha-Fetoprotein Inhibits Macrophage Expression of la Antigens," The Journal of Immunology 132:1722-1727 (1984).			
	Masuda et al., "Selective Antitumor Effect of Thioether-Linked Immunotoxins Composed of Gelonin and Monoclonal Antibody to Alpha-Fetoprotein or its F(ab') ₂ Fragment," <i>Tumor Biol.</i> 15:175-183 (1994).			
	Mizejewski, "Alpha-Fetoprotein Testing: Regulatory and Technical Considerations," Laboratory Management (1987).			
	Morinaga et al., "Primary Structures of Human Alpha-Fetoprotein and its mRNA," Proc. Natl. Acad. Sci. USA 80:4604-4608 (1983).			
RAW	Moro et al., "Monoclonal Antibodies Directed Against a Widespread Oncofetal Antigen: The Alpha-Fetoprotein Receptor," <i>Tumor Biol.</i> 14:116-130 (1993).			
XAMINER	DATE CONSIDERED			
	itlal citation considered. Draw line through citation if not in conformance and not considered. Include copy of thiext communication to applicant.			

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	06727/012001
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No. Applicant	10/624,380
		Applicant	Robert Mulroy et al.
STATEMEN'	ON DISCLOSURE T BY APPLICANT	Filing Date	July 22, 2003
(Use several s	theets if necessary)	Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TIT	LE, DATE, PLACE OF PUBLICATION)			
RAW	Murgita et al., "Adult Murine T Cells Activated in Vitro by Alpha-Fetoprotein and Naturally Occurring T Cells in Newborn Mice: Identity in Function and Cell Surface Differentiation Antigens," Proc. Natl. Acad. Sci. USA 75:2897-2901 (1978).				
	Murgita et al., "Alpha-Fetoprotein Induces Suppressor	T Cells in Vitro," Nature 267:257-259 (1977).			
	Murgita et al., "Characterization of Murine Newborn Inl Comparison with an Adult T Cell Subset Activated in V (1981).	nibitory T Lymphocytes: Functional and Phenotypic itro by Alpha-Fetoprotein," Eur. J. Immunol. 11:957-964			
	Murgita et al., "Effects of Human Alpha-Foetoprotein o Exp. Immunol. 33:347-356 (1978).	n Human B and T Lymphocyte Proliferation in Vitro," Clin			
	Murgita et al., "The Effects of Mouse Alpha-Fetoprotein Responses in Vitro," Scand. J. Immunol. 5:1215-1220	n on T-Cell-Dependent and T-Cell-Independent Immune (1976).			
	Murgita, "The Immunosuppressive Role of Alpha-Feton 1014 (1976).	protein During Pregnancy," Scand. J. Immunol. 5:1003-			
	Murgita et al., "Regulation of Immune Functions in the	Fetus and Newborn," Prog. Allergy 29:54-133 (1981).			
	Murgita et al., "Selective Immunoregulatory Properties (1979).	gulatory Properties of Alpha-Fetoprotein,* La Ricerca Clin. Lab. 9:327-342			
	Murgita et al., "Suppression of the Immune Response Feloprotein on the Primary and Secondary Antibody Re 286 (1975).	by Alpha-Fetoprotein I. The Effect of Mouse Alpha- esponse," <i>The Journal of Experimental Medicine</i> 141:269			
	Murgita et al., "Suppression of the Immune Response Fetoprotein on Mixed Lymphocyte Reactivity and Mitog Experimental Medicine 141:440-452 (1975).	by Alpha-Fetoprotein II. The Effect of Mouse Alpha- len-Induced Lymphocyte Transformation," The Journal of			
	Nelson et al., "Maternal-Fetal Disparity in HLA Class II Rheumatoid Arthritis," The New England Journal of Me	Alloantigens and the Pregnancy-Induced Amelioration of adicine 329:466-471 (1993).			
	Nishi et al., "Expression of Rat Alpha-Fetoprotein cDN, 972 (1988).	A in Escherichia coli and in Yeast," J. Biochem. 104:968-			
	O'Neill et al., "Regulation of Human Lymphocyte Activa Suppression of la-Associated T-Cell Proliferation in Vit (1982).	ation by Alpha-Fetoprotein: Evidence for Selective ro,* Oncodevelopmental Biology and Medicine 3:135-150			
RAW	Peck et al., "Cellular and Genetic Restrictions in the Im Inhibition of Anti-la-Associated Proliferative Reactions,	munoregulatory Activity of Alpha-Fetoprotein I. Selective J. Exp. Med. 147:667-683 (1978).			
XAMINER	DAT	E CONSIDERED			

SUBSTITUTE FORM PTO-1449 U.S. DI	EPARTMENT OF COMMERCE	Attorney Docket No. 06727/012	06727/012001
(MODIFIED) PATER	IT AND TRADEMARK OFFICE	Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
INFORMATION DISC STATEMENT BY API	Filing Date	July 22, 2003	
(Use several sheets if necessary)		Group	1632
(37 C.F.R. § 1.98(b))	IDS Filed	March 28, 2005	
		Customer Number	21559

RAW	Peck et al., "Cellular and Genetic Restriction Fetoprotein-Induced Suppression of Cytotox	ns in the Immunoregulatory Activity of Alpha-Fetoprotein II. Alphacic T Lymphocyte Development," <i>J. Exp. Med.</i> 148:360-372 (1978).			
	Peck et al., "Cellular and Genetic Restrictions in the Immunoregulatory Activity of Alpha-Fetoprotein III. Role of the MLC-Stimulating Cell Population in Alpha-Fetoprotein-Induced Suppression of T Cell-Mediated Cytotoxicity, <i>J. of Immunology</i> 128:1134-1140 (1982). Sambrook et al., "Expression of Cloned Genes in <i>Escherichia coli</i> ," <i>Molecular Cloning</i> 17:1-44 (1989). Sell, "Alphafetoprotein," <i>Cancer Markers Diagnostic and Develpmental Significance</i> 249-293 (1980). Semeniuk et al., "Immunoregulation by Recombinant Alpha-Fetoproteins Produced in Eukaryotic and Prokaryotic Expression Systems," Abstract 2799, <i>Experimental Biology</i> 94 TM (1994). Soto et al., "Control of Growth of Estrogen-Sensitive Cells: Role for Alpha-Fetoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 77:2084-2087 (1980). Van Oers, et al., "Isolation and Characterization of a Distinct Immunoregulatory Isoform of Alpha-Fetoprotein Produced by the Normal Fetus," <i>J. Exp. Med.</i> 170:811-825 (1989). Van Oers et al., "Analytical- and Preparative-Scale Separation of Molecular Variants of Alpha-Fetoprotein by Anion-Exchange Chromatography on Monobead TM Resins," <i>Journal of Chromatography</i> 525:59-69 (1990). Villacampa et al., "Alpha-Fetoprotein Receptors in a Human Breast Cancer Cell Line," <i>Biochemical and Biophysical Research Communications</i> 122:1322-1327 (1984).				
			RAW	Yamamoto et al., "Expression of Human Alpha-Fetoprotein in Yeast," Life Sciences 46:1679-1686 (1990).	
			EXAMINER	/Robert A. Wax/	DATE CONSIDERED 09/15/2006